BridgeBio Oncology Therapeutics Appoints Dr. Yong Ben as Chief Medical and Development Officer
Slice of Healthcare Team
Sep 11, 2024
Key Highlights
- Yong (Ben) Ben, MD, appointed as Chief Medical and Development Officer at BBOT.
- Dr. Ben brings over 25 years of drug development expertise to BBOT.
- Key clinical programs include BBO-8520, BBO-10203, and BBO-11818.
- Dr. Ben's prior achievements include approvals for IMFINZI® and NINLARO®.
Source: Business Wire
Notable Quotes
“ Ben is a highly accomplished leader with an outstanding record in drug development. ”
Eli Wallace, PhD, Chief Executive Officer at BBOT
“ I look forward to contributing to the advancement of our clinical programs and making a significant impact on patient care. ”
Yong (Ben) Ben, MD, Chief Medical and Development Officer at BBOT
